Close Menu

PARP inhibitors

After five years, nearly half the Lynparza-treated patients in the SOLO-1 trial remained disease-free, compared with one-fifth of those who received placebo.

Results of the randomized Phase III BROCADE trial, recently published in The Lancet Oncology, suggested a benefit of veliparib combined with platinum-based chemotherapy.

Senaparib is currently being studied in a Phase II trial as a monotherapy for BRCA-mutated ovarian cancer patients who have received at least two prior lines of therapy.

Both drugs are being investigated in cancer patients harboring biomarkers detected by the company's drug response predictor platform.

Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.

With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.

Metastatic prostate cancer patients with BRCA, PALB2, FANCA, and CDK12 mutations had an improved response than those without such mutations, a study showed.

Radboud University Medical Center researchers developed and validated the single-molecule molecular inversion probe-centered workflow for more efficient BRCA1/2 testing.

Researchers found tumor and microenvironment features of advanced ovarian cancers respond to combination PARP inhibitor and immune checkpoint treatment.

The intended use will be in newly diagnosed ovarian cancer patients who are responsive to platinum chemotherapy regardless of biomarker status.

Pages